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ABSTRACT
Although melatonin oncostatic and cytotoxic effects have been described in 
different types of cancer cells, the specific mechanisms leading to its antitumoral effects 
and their metabolic context specificity are still not completely understood. Here, we 
evaluated the effects of melatonin in P19 embryonal carcinoma stem cells (CSCs) and 
in their differentiated counterparts, cultured in either high glucose medium or in a 
galactose (glucose-free) medium which leads to glycolytic suppression and increased 
mitochondrial metabolism. We found that highly glycolytic P19 CSCs were less 
susceptible to melatonin antitumoral effects while cell populations relying on oxidative 
metabolism for ATP production were more affected. The observed antiproliferative 
action of melatonin was associated with an arrest at S-phase, decreased oxygen 
consumption, down-regulation of BCL-2 expression and an increase in oxidative 
stress culminating with caspase-3-independent cell death. Interestingly, the combined 
treatment of melatonin and dichloroacetate had a synergistic effect in cells grown in 
the galactose medium and resulted in an inhibitory effect in the highly resistant P19 
CSCs. Melatonin appears to exert its antiproliferative activity in P19 carcinoma cells 
through a mitochondrially-mediated action which in turn allows the amplification of 
the effects of dichloroacetate, even in cells with a more glycolytic phenotype.
INTRODUCTION
Melatonin (N-acetyl-5-methoxytryptamine), the main 
pineal hormone that relays light/ dark cycle information to 
the circadian system, can also be produced in other tissues 
[1]. Melatonin amphiphilic characteristics allow it to 
reach any cell, compartment or body fluid [2]. Besides its 
well-known functions in circadian and seasonal rhythms, 
melatonin and its metabolites also decrease oxidative 
stress by acting both as direct free radical scavenger and 
by stimulating the activity and expression of antioxidant 
enzymes [3–6]. Additionally, several other activities have 
been attributed to melatonin: the regulation of the immune 
system [7], the modulation of mitochondrial activity [8], as 
well as regulation of cell death [9] and autophagy [10], and 
an intrinsic antitumoral activity [11]. Due to the multitude 
of its actions, a role in maintaining healthy aging has been 
ascribed to melatonin [12].
Two models have been proposed to explain tumor 
heterogeneity: the stochastic model that assumes that 
all cancerous cells have the ability to proliferate and 
regenerate a tumor [13] and the cancer stem cell model that 
hypothesizes that similarly to normal tissues, tumors are 
composed of a mixed population of cells at varying states 
of differentiation. These differentiated cancer cells (dCCs) 
are typically unable to initiate a tumor and normally derive 
from stem-like counterparts with the ability to proliferate 
indefinitely. Recently, a new cancer stem cell hypothesis 
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suggests that cancer stem cells could be mostly originated 
from stochastic effects during DNA replication in normal 
adult stem cells [14]. Regardless of the true mechanism, 
cancer stem cells are considered the driving force 
behind cancer development and progression. It is believed 
that cancer stem cell differentiation leads to the production 
of multiple lineages ultimately forming the tumor bulk 
[15]. In this regard, cancer stem cells have emerged as 
an important chemotherapeutic target, as their ability to 
evade treatments provides a likely explanation for tumor 
re-growth. Although cancer stem cells were only initially 
described in 1997 for acute myeloid leukemia [16], they 
have been further identified and isolated from bone marrow, 
brain, breast, pancreas, skin, neck, nervous system, colon 
and prostate cancers [17, 18]. Approaches to eliminate 
cancer stem cells and avoid tumor re-growth include the 
depletion of tumor blood supply, differentiation therapies, 
developmental signaling pathways, DNA checkpoint 
proteins, and modulation of the cellular redox state [18–20].
P19 embryonal carcinoma stem cells (CSCs) 
constitute an appropriate model for the study of cancer 
stem cell maintenance and differentiation. In fact, upon its 
loss of pluripotency through differentiation with retinoic 
acid these cells retain their immortalized phenotype [21, 
22]. We had previously observed that P19 CSCs possess 
specific mitochondrial and metabolic properties that are 
altered during cell differentiation. These properties are 
inter-connected with pluripotency and resistance to the 
mitochondrial agent dichloroacetate. Thus, the stimulation 
of mitochondrial activity by culturing P19 stem cells in 
galactose (glucose-free), glutamine/pyruvate- containing 
medium reduced their glycolytic phenotype and 
stemness, triggered cell differentiation, and increased the 
susceptibility of P19 cells to dichloroacetate [23].
Although sufficient evidence supports the antitumoral 
function of melatonin in some tumor types [24], little is 
known about the functional effects of this indolamine in 
cancer cells expressing a stem cell-like phenotype and, 
particularly, how that effect depends on mitochondrial 
activity. In general, factors which allow melatonin to 
recognize context specificity and induce apoptosis in some 
types of cancer cells only are not completely known [24]. 
In the present study, we analyze the effect of melatonin 
in the P19 CSCs model which allows testing the effect 
of different molecules in distinct metabolic contexts and 
stemness stages. Interestingly, we found that only cells 
relying on a more oxidative metabolism for ATP production 
were susceptible to melatonin. Thus, this work aims the 
understanding of the mechanisms that make these cells 
vulnerable to melatonin in comparison with their glycolytic 
counterparts.
RESULTS
The P19 cell model allows testing the effects of 
melatonin on the same cancer cell line within different 
degrees of pluripotency, differentiation and mitochondrial 
activity [23].
Melatonin decreased P19 cell mass only when 
oxidative metabolism was used for  
ATP production
To assess the effect of different concentrations of 
melatonin (0.001, 0.01, 0.1 and 1 mM) on P19 four stages 
of differentiation (Glu-CSCs, Glu-dCCs, Gal-CSCs and 
Gal-dCCs), cell mass was evaluated after 24, 48, 72 and 
96 hours of treatment. The decreasing effect of melatonin 
on cell mass was dependent on the medium used for 
cell growth. At 72 hours of incubation, 1 mM melatonin 
significantly decreased Gal-CSCs and Gal-dCCs cell mass, 
which was more evident in Gal-dCCs (Figure 1A). In fact, 
the concentration required for half maximal inhibitory 
effect was considerably lower in Gal-dCCs than in Gal-
CSCs (Table 1).
The trypan blue dye exclusion assay was carried out 
to determine the effects on cell viability after 72 hours 
of treatment with 0.1 and 1 mM melatonin (Figure 1B). 
Hence, only cells cultured in galactose (glucose-free), 
glutamine/pyruvate- containing media which relied 
more in oxidative metabolism for ATP production were 
susceptible to 1 mM melatonin (p < 0.01). Considering 
these observations, one can ask what makes these cells 
more susceptible to melatonin in comparison to their high 
glucose medium counterparts.
Melatonin reduced intracellular calcium 
concentration and induced S-phase arrest  
in P19 cells grown in the modified  
galactose-containing media
In order to verify whether the effect of melatonin was 
mediated by any alteration on cell cycle progression, flow 
cytometry analysis with propidium iodide was performed 
in the four groups of P19 cells treated with melatonin (0.1 
and 1 mM) during 72 hours. As expected, all differentiated 
P19 cell groups generated by either the addition of retinoic 
acid (Glu-dCCs, Gal-dCCs) or by culture in the modified 
galactose-containing medium (Gal-CSCs), presented 
differences regarding cell cycle progression when 
compared to the undifferentiated group. Thereby, Gal-CSCs 
significantly increased the percentage of cells in G1/G0 
phase at expenses of reducing cells at S-phase (p < 0.001 
vs. Glu-CSCs). Moreover, P19 Glu-dCCs presented an arrest 
on G2/M phase (p < 0.001) when compared to their stem 
counterpart (Glu-CSCs). Similarly, P19 Gal-dCCs prolonged 
its G2/M phase at the expense of a reduction on G1/G0 phase 
(p < 0.05) when compared to Gal-CSCs. Therefore, when 
compared to the groups previously shown to be more resistant 
to melatonin (P19 cells grown on high glucose medium), all 
other groups of P19 cells showed a significant decrease in 
S-phase after treatment with melatonin.
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The effect of melatonin on cell cycle progression 
was dependent on the metabolic and differentiation status 
of the cells. In this regard, 1 mM melatonin 72 hours 
treatment induced an arrest at G2/M and G1/G0 phases 
respectively for the resistant Glu-CSCs and Glu-dCCs 
groups (p < 0.05). On the other hand, 1 mM melatonin 
induced an arrest at S-phase in both P19 cell groups 
cultured in galactose (glucose-free), glutamine/pyruvate- 
containing medium (p < 0.001) at expenses of reducing the 
number of cells on G2/M phase for Gal-CSCs, and on G1/
G0 phase for Gal-dCCs (Figure 1C).
Melatonin modulates calcium homeostasis [25], a 
critical step to maintain a regular cell cycle progression. 
The four groups of P19 cells showed different basal 
levels of intracellular free calcium, being the highest 
concentration observed in P19 cells grown in galactose 
(glucose-free), glutamine/pyruvate- containing medium. 
In these groups of P19 cells cultured in the modified 
galactose media, 1 mM melatonin along 72 hours 
treatment resulted in decreased amount of free calcium 
(p < 0.05) in clear contrast to the results in the resistant 
Glu-CSCs (Figure 1D).
Melatonin altered mitochondrial membrane 
potential, oxygen consumption and ATP  
content in P19 cells
Considering that the antiproliferative action of 
melatonin was only observed in P19 cells with active 
mitochondrial metabolism, we propose that this effect may 
be mediated through a direct interaction with the referred 
organelle.
In all P19 cell groups, melatonin increased 
mitochondrial membrane potential, reaching significant 
values with 1 mM melatonin for both groups of CSCs 
(Glu-CSCs and Gal-CSCs) and with 0.1 mM melatonin for 
both dCCs groups (Figure 2A). Since the mitochondrion 
couples the maintenance of mitochondrial membrane 
potential with electron transport in the respiratory chain 
and with ATP synthesis, we next measured mitochondrial 
respiration. Figure 2B shows no effects on basal 
oxygen consumption in glycolytic Glu-CSCs treated 
with melatonin. In contrast, melatonin decreased basal 
respiration of more oxidative cells (Glu-dCCs, Gal-CSCs, 
Gal-dCCs), which was especially relevant for cells grown 
Figure 1: Melatonin showed antiproliferative effects only in P19 cells which were reliable in oxidative metabolism 
for ATP production. Melatonin effects on cell viability were measured in the four types of P19 cells: stem (CSCs) and differentiated 
(dCCs) lines, growing in glucose (Glu) and in modified galactose (Gal)-containing media. A. The sulforhodamine B (SRB) assay shows a 
cytotoxic effect of 1mM melatonin in Gal-CSCs and Gal-dCCs. Data represent the average percentage of SRB absorbance with respective 
time 0 ± SEM from at least three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001 vs. control. B. Cell viability determined 
by trypan blue dye exclusion assay after 72 hours of treatment with melatonin confirms the resistance of P19 cells cultured in high glucose 
medium. Data are expressed as percentage of live cells ± SEM from at least three independent experiments. * vs. control; a vs. Glu-CSCs. 
C. Cell cycle was analyzed by flow cytometry using propidium iodide in the four types of P19 cancer cells, untreated (Ctr) and treated with 
melatonin (0.1 and 1 mM) during 72 hours. Data are expressed as percentage of cells in G1/G0, S and G2/M ± SEM from three independent 
experiments. D. Intracellular levels of free calcium were detected by Fluo-4 fluorescence. Data are means ± SEM from at least three 
separate experiments. Statistical comparisons: * vs. Ctr; a vs. Glu-CSCs; b vs. Gal-CSCs; c vs. Glu-dCCs. The number of symbols marks 
the level of statistical significance: one for p < 0.05, two for p < 0.01, and three for p < 0.001.
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in galactose medium (p < 0.01). Interestingly, 10 μM 
FCCP increased oxygen consumption only in Glu-CSCs 
(p < 0.001) and did not increase oxygen consumption up 
to a similar maximal capacity in melatonin-treated groups 
which were shown to have decreased basal respiration 
levels. Furthermore, although basal oxygen consumption 
was not affected by melatonin in Glu-CSCs, the addition of 
FCCP to cells treated with 1 mM melatonin did not result 
in increased respiration, suggesting that melatonin impairs 
respiration even in the high glycolytic and resistant Glu-
CSCs. Overall, these results point out for a direct action 
of melatonin on the mitochondrial electron transport 
chain in all groups of P19 cells, especially in those with 
an active oxidative metabolism. Conversely, its effects on 
the mitochondrial transmembrane electric potential suggest 
another target. Intriguingly, 1 mM melatonin significantly 
increased ATP content in Glu-CSCs, Gal-CSCs and Gal-
dCCs (Figure 2C). Despite this, both ADP and AMP levels, 
as well as energy charge and the percentage of ATP in the 
total adenine nucleotide pool remained unchanged after 
treatment with melatonin in the four groups of P19 cells.
Melatonin showed a pro-oxidant effect,  
reduced BCL-2 expression and induced a  
caspase-3-independent cell death in P19 cells 
with oxidative metabolism
The disruption of the mitochondrial electron transport 
chain results in a higher reactive oxygen species (ROS) 
production [26]. Differentiated P19 cells (Glu-dCCs and 
Gal-dCCs) presented higher malondialdehyde (MDA) 
content, a classical marker of oxidative stress, when 
compared to their stem counterparts (p < 0.001). Similarly, 
cells cultured in galactose (glucose-free), glutamine/
pyruvate- containing media (Gal-CSCs and Gal-dCCs) also 
presented higher MDA content than their high glucose-
cultured counterparts. Despite these basal differences, 1 mM 
melatonin significantly increased MDA levels in all P19 cell 
groups compared to their corresponding controls (p < 0.001), 
especially in cells cultured in galactose medium (Figure 
2D). This effect may be related with the ability of melatonin 
to decrease the proliferation rate of highly oxidative cells. 
Intriguingly, although 0.1 mM melatonin also impacted 
oxygen consumption of cells cultured in galactose media, 
this concentration also exhibited an antioxidant effect.
Since excessive ROS production by mitochondria 
plays a preponderant role in mitochondrial outer 
membrane permeabilization, we investigated alterations 
in BCL-2 and BAX protein content. We found no 
changes in BAX content in whole-cell extracts in any 
of the analyzed cell groups. However, melatonin-treated 
cells cultured in galactose media showed a decreased 
content of the antiapoptotic protein BCL-2, while this 
effect was not found when cells were grown in high 
glucose media (Figure 3A). The observed decrease of 
BCL-2 content in melatonin-treated and galactose-
cultured cells suggests that the intrinsic apoptotic 
pathway may have been activated. However, our data 
did not show the expected increase in caspase-3-like 
activity (Figure 3B). Interestingly, untreated Gal-CSCs 
show the highest activity of caspase-3 when compared 
to Glu-CSCs (p < 0.001). This observation may occur 
as consequence of the forced metabolic remodeling and 
its associated differentiation process induced by the 
galactose (glucose-free), glutamine/pyruvate- containing 
medium. Nonetheless, the calcein-AM and propidium 
iodide Live/Dead assay confirmed that 1 mM melatonin 
increases the percentage of dead cells (calcein-/
propidium iodide+) in cell populations with higher 
mitochondrial metabolism (Gal-CSCs and Gal-dCCs; 
p < 0.001). Moreover, this effect was also detected in 
Glu-dCCs (p <0.001) where a tendency for decreased 
viability was measured by the trypan blue assay. Finally, 
0.1 mM melatonin also increased the percentage of dead 
cells but only in cells grown in galactose (glucose-free), 
glutamine/pyruvate- containing medium (Figure 3C).
Table 1: Computing simulation for obtaining the half maximal inhibitory concentration and the 
combination index in P19 cells treated with dichloroacetate (DCA) and melatonin (MEL)
IC50(mM) CI
MEL DCA 10 mM DCA + 0.1 mM MEL 10 mM DCA + 1 mM MEL
Glu-CSCs n/a 52.915 n/a n/a
Glu-dCCs n/a 9.955 n/a n/a
Gal-CSCs 1.930 19.988 0.954 0.273
Gal-dCCa 0.024 14.360 2.052 0.496
Dose-response values IC50 (dose required for median effect) and the combination index (CI) were obtained with CompuSyn 
software for drug combinations and for general dose effect analysis, using data from cell mass studies in P19 embryonal 
carcinoma stem cells (CSCs) and differentiated cancer cells (dCCs) grown in glucose media (Glu) and in glucose-free 
galactose-containing media (Gal). The CI value reflects the extent of synergy or antagonism: CI < 0.9, synergy; 0.9 < CI  
< 1.1, additive effect; CI > 1.1, antagonism. n/a: not applicable.
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Dichloroacetate enhanced the antiproliferative 
effect of melatonin
The above results suggest that melatonin antitumor 
effects are dependent on cellular oxidative metabolism 
and are caspase-3 activity-independent. Therefore, 
Glu-CSCs presented a resistant profile which might be 
related to their predominantly glycolytic metabolism. 
As melatonin appears to affect only cells relying on 
mitochondrial metabolism, we next questioned whether 
a combined treatment with dichloroacetate could affect 
Glu-CSCs. As shown in Figure 4A, co-treatment with 
10 mM dichloroacetate and 1 mM melatonin resulted 
in decreased Glu-CSCs cell mass (p < 0.01 and p < 
0.001 for 48 and 72 hours of treatment, respectively). 
Although the calculated combination index with 10 mM 
dichloroacetate and 0.1 mM melatonin suggested 
additive and antagonistic effects in Gal-CSCs and 
Gal-dCCs respectively, the combination of 10 mM 
dichloroacetate with 1 mM melatonin clearly exerted 
a synergistic effect in both groups of galactose media-
grown cells (Table 1). As dichloroacetate activates 
pyruvate dehydrogenase (PDH) by inhibiting pyruvate 
dehydrogenase kinase (PDHK), we evaluated phos-
pho(Ser293)-PDH after 72 hours treatment with 1 
mM melatonin and 10 mM dichloroacetate. However, 
treatment with dichloroacetate alone was able to 
significantly reduce phospho(Ser293)-PDH in Glu-CSCs, 
Glu-dCCs and Gal-dCCs. Furthermore, treatment with 
melatonin, alone or in combination with dichloroacetate, 
did not alter the phosphorylation status of PHD in all 
types of P19 cells with the exception of Gal-dCCs where 
a significant decrease of phospho(Ser293)-PDH (p < 
0.05) was observed (Figure 4B). Although our results 
Figure 2: Melatonin altered mitochondrial membrane potential, oxygen consumption and ATP production in P19 
cells. A. Accumulation of the potentiometric dye tetramethylrhodamine methyl ester (TMRM) was measured by flow cytometry in all 
experimental groups: stem (CSCs) and differentiated (dCCs) P19 cells, growing in glucose (Glu) and in modified galactose (Gal)-containing 
media, and treated with 0.1 and 1 mM melatonin during 72 hours. Data are shown as relative fluorescence units (RFU) that represent 
the mean average of geometric mean values ± SEM from at least three independent experiments. Carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP) (2 μM) was used as negative control. Statistical comparisons: * vs. control; # vs. 0.1 mM melatonin. B. Oxygen 
consumption displayed as nmol of O
2
 per minute and per 106 cells was decreased after the treatment with melatonin in Glu-dCCs, Gal-
CSCs and Gal-dCCs. Ten μM FCCP was added to test maximal respiration. Data are means ± SEM from at least three independent 
experiments. Statistical comparisons: * vs. control; # vs. 0.1 mM melatonin; † vs. basal. C. ATP, ADP and AMP measurements obtained 
by high-performance liquid cromatography and expressed as pmol per mg of protein indicated an increased ATP production after 72 hours 
of treatment with 1 mM melatonin, particularly in cells cultured in galactose medium. Data are means ± SEM from n = 6 experiments. 
D. Measurement of malondialdehyde (MDA) by high-performance liquid cromatography in the four groups of P19 cells revealed an increased 
lipid peroxidation after 72 hours of treatment with 1 mM melatonin, especially in cells cultured in modified galactose medium. Data are 
means ± SEM for n = 6 experiments. Statistical comparisons: * vs. control; # vs. 0.1 mM melatonin; a vs. Glu-CSCs; b vs. Gal-CSCs; c vs. 
Glu-dCCs. The number of symbols marks the level of statistical significance: one for p < 0.05, two for p < 0.01, and three for p < 0.001.
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suggest that this pathway might not be directly involved 
in melatonin effects, the result from the co-treatment 
in Glu-CSCs and the decrease in phospho(Ser293)-
PDH observed in melatonin-treated Gal-dCCs revealed 
significant information about the possible contribution 
of this pathway.
To determine whether apoptosis-inducing 
factor (AIF) release from mitochondria is involved 
in the antiproliferative effects elicited by melatonin, 
and possibly confirm caspase-independent cell 
death, we measured AIF content in mitochondrial 
and cytosolic fractions. The results showed a higher 
cytosolic 67-kDa AIF content in Glu-CSCs and in 
both types of galactose media-grown P19 cells either 
treated with melatonin alone or in combination with 
dichloroacetate (p < 0.05). Besides the observed 
increase in cytosolic 67-kDa AIF content, an 
additional cytosolic band of ~57 kDa was identified 
in melatonin-treated cells grown in galactose medium 
(Gal-CSCs and Gal-dCCs) and in Glu-dCCs treated 
with both melatonin and dichloroacetate. This additional 
band is likely to correspond to a form of AIF which 
translocates to the nucleus where it triggers caspase-3-
independent type of cell death [27] (Figure 5).
DISCUSSION
Several metabolic properties distinguish cancer 
cells from normal healthy cells [28], including a 
decreased mitochondrial ATP production under 
normoxia, a phenomenon termed Warburg effect [29–31]. 
Similarly, normal stem cells rely on glycolysis for ATP 
production. In fact, a recent report suggests that cancer 
initiating cells may be mostly derived from normal 
adult stem cells [14]. However, the exact mechanisms 
by which cancer cells maintain an anaerobic metabolism 
in the presence of oxygen and the relationship between 
carcinogenesis and stem cell metabolism are not 
completely understood [32]. We have previously 
documented the different metabolic signatures of P19 
CSCs and dCCs. P19 CSCs are highly glycolytic and 
their differentiation is characterized by a more oxidative 
metabolism marked by a noticeable mitochondrial 
remodeling. Although P19 CSCs and dCCs have similar 
Figure 3: Melatonin induced caspase-3-independent cell death in P19 cells presenting oxidative metabolism. A. Protein 
levels of BCL-2 and BAX revealed no changes in BAX content but evident alterations in BCL-2 especially after treating P19 cells cultured 
in galactose with melatonin. Treatments: control (C), melatonin 0.1 mM (0.1), and melatonin 1 mM (1). Bar charts show means of optical 
density (O.D.) ± SEM expressed as percentage of Glu-CSCs, from at least three separate immunoblots. B. Caspase-3-like activity determined 
in the four types of P19 cells: P19 stem (CSCs) and differentiated (dCCs) cells, grown in glucose (Glu) and modified galactose media (Gal), 
using DEVD linked to p-nitroaniline (pNA) was not induced by the treatment with melatonin during 72 hours. Data are expressed as means 
(nmol pNA per minute and mg protein) ± SEM from at least three independent experiments. C. However, live/dead assay with calcein-
AM and propidium iodide (PI) showed a higher percentage of dead cells (calcein-/PI+) in melatonin-treated cells which present a higher 
oxidative metabolism (Glu-dCCs, Gal-CSCs and Gal-dCCs). Data are expressed as percentage of viable cells (calcein+/PI-), dead cells 
(calcein-/PI+), and cell debris (calcein-/PI-) ± SEM from at least three independent experiments. Statistical comparisons: * vs. control; # 
vs. 0.1 mM melatonin; a vs. Glu-CSCs; b vs. Gal-CSCs. The number of symbols marks the level of statistical significance: one for p < 0.05, 
two for p < 0.01, and three for p < 0.001.
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amounts of mitochondria, these organelles undergo 
profound changes in their morphology, biogenesis and 
physiology along the differentiation process, culmi-
nating with the establishment of a long filamentous, 
polarized and active network [23]. These alterations are 
accompanied by reduction in stemness and cell growth 
suggesting a link between pluripotency, proliferation 
and mitochondrial metabolism. In fact, when forcing 
mitochondrial metabolism by growing P19 cells in 
galactose (glucose-free), glutamine/pyruvate- containing 
medium (Gal-CSCs), cells increase their mitochondrial 
activity, reduce proliferation and pluripotency and, 
spontaneously, differentiate. In addition, when P19 Gal-
CSCs are treated with retinoic acid, the resultant cells 
(Gal-dCCs) show the highest degree of mitochondrial 
development and function [23].
The glycolytic metabolism observed in P19 CSCs 
is also linked with a drug-resistant phenotype. Thus, P19 
CSCs were shown to be resistant to dichloroacetate, a 
mitochondrial drug that reverses the abnormal metabolism 
of cancer cells by shifting it from glycolysis to glucose 
oxidation [23]. This mitochondria-mediated cell death 
suppression seems to be a common feature among 
different types of CSCs [33].
As the mechanism by which melatonin is cytotoxic 
towards some cancer cells is still uncertain, the present work 
investigates the impact of cell differentiation and metabolism 
on melatonin action. This was achieved by using P19 cells 
at four different differentiation stages: Glu-CSCs, Glu-
dCCs, Gal-CSCs, and Gal-dCCs. The results obtained here 
revealed that melatonin did not affect high glucose-grown 
CSCs. In fact, only cells which rely more in oxidative 
phosphorylation for ATP synthesis, particularly those cells 
grown in galactose medium were susceptible to the highest 
concentration of melatonin (1 mM). In addition, inhibition 
of proliferation by melatonin was also observed in Gal-dCCs 
at lower concentrations. As stated above, Gal-dCCs are the 
cell group with the largest degree of cell differentiation, 
morphological heterogeneity (Supplementary Figure S1) 
and up-regulated mitochondrial function, which make 
these cells more susceptible to antiproliferative agents. In 
agreement, we have previously demonstrated that Gal-dCCs 
present a more open conformation of the mitochondrial 
permeability transition pore that is not able to respond to 
cyclosporin A [23]. Resistance to drug therapy constitutes 
an important hallmark of CSCs, which seems to be strongly 
related with an altered cell metabolic profile. Accordingly, 
some tumor cells are unable to produce ATP in a 
Figure 4: Effect of the combined treatment with melatonin and dichloroacetate (DCA) in P19 embryonal carcinoma 
stem (CSCs) and differentiated (dCCs) cells, grown in glucose (Glu) and galactose (Gal) media. A. The sulforhodamine 
B (SRB) assay shows a decrease in cell mass after 72 hours of the combined treatment of the Glu-CSC group with 1 mM melatonin 
and 10 mM dichloroacetate. Data represent the average percentage of SRB absorbance with respective time 0 ± SEM from at least four 
independent experiments. B. Content of pyruvate dehydrogenase (PDH) and PDH-subunit E1α phosphorylated at Ser293 site in the four 
types of P19 cells studied reveals that melatonin was only able to contribute to dichloroacetate effect by reducing PDH phosphorylation in 
Gal-dCCs. Treatments: control (C), melatonin 1 mM (M), dichloroacetate 10 mM (D), and melatonin 1 mM + dichloroacetate 10 mM 
(M+D). Ponceau S was used to normalize sample loading. Bar charts show means of normalized optical density (O.D.) expressed as 
percentage of control ± SEM from three separate immunoblots. *p < 0.05; **p < 0.01; ***p < 0.001 vs. control.
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mitochondria-dependent manner resulting in a mitochondrial-
apoptosis resistant phenotype [28, 33] that is also 
characteristic of many stem cells [34]. Our present results 
suggest that melatonin-dependent antiproliferative effect 
requires an active mitochondrial metabolism. Therefore, if 
melatonin acts throughout a mitochondria-mediated manner, 
lower concentrations of melatonin would be expected to be 
more efficient in revealing its antiproliferative effects in 
Gal-dCCs than in other types of P19 cells expressing a more 
resistant and undifferentiated phenotype. It is known that the 
cytostatic or cytotoxic effects of melatonin in tumor cells 
vary depending on the cell type and its concentration, being 
the antiapoptotic actions of melatonin typically described 
at millimolar concentrations only in specific cancer types 
[11]. Consequently, our findings highlight the importance of 
mitochondrial and cell differentiation therapies when using 
melatonin against cancer cells with more undifferentiated 
stem cell-like signatures.
Embryonic stem cells (ESCs) exhibit a special cell 
cycle structure that plays a role in stem cell maintenance 
[35], being characterized by short G1 and G2 phases 
and by a high proportion of cells in S-phase. In fact, the 
stem cell cycle plays a role in the regulation of cell fate 
decisions [36]. We found that cell cycle is remodeled to 
the canonical cycle with prolonged G1 phase when P19 
cells are forced to rely on mitochondrial metabolism for 
ATP production. Under these conditions, melatonin had a 
higher effect and induced an arrest at S-phase. However, 
this arrest at S-phase induced by high doses of melatonin 
was not equivalent in Gal-CSCs and Gal-dCCs since it 
was produced at the expenses of reducing the number of 
Gal-CSCs cells on G2/M phase and Gal-dCCs cells on G1/
G0 phase. These differences may come as consequence 
of the heterogeneity within cell populations. Both types 
of cells, Gal-CSCs and Gal-dCCs, are composed of a 
range of different cell populations with different cell 
cycle regulation, morphology, growth rate, differentiation 
patterns and metabolism [23] that may lead to divergent 
responses upon melatonin treatment. In glycolytic and 
resistant cells, melatonin induced alternative types of cell 
Figure 5: Representative immunoblot images for apoptosis-inducing factor (AIF) in cytosolic and mitochondrial 
extracts from P19 stem (CSCs) and differentiated (dCCs) cells, grown in glucose (Glu) and galactose (Gal) media, 
show a higher cytosolic localization of ~57 kDa form of AIF in cells grown in galactose media, treated with melatonin, 
alone or in combination with dichloroacetate. Treatments: control (C), melatonin 1 mM (M), dichloroacetate 10 mM (D), and 
melatonin 1 mM + dichloroacetate 10 mM (M+D). Ponceau S and TOM20 were used to normalize sample loading in cytosolic and 
mitochondrial extracts, respectively. Bar charts show means of normalized optical density (O.D.) ± SEM, from at least three separate 
immunoblots. Statistical comparisons: *p < 0.05; **p < 0.01; ***p < 0.001 vs. control. n/a: no band detected (O.D. = 0).
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cycle arrest, namely at phases G2/M and G1/G0 in Glu-
CSCs and Glu-dCCs respectively. Recent studies reported 
different results regarding cell cycle progression in cancer 
cells treated with melatonin. In human colorectal cancer 
cells, melatonin decreased the S-phase population and 
induced cell death [37], whereas in osteosarcoma and 
leukemia cells, melatonin reduced the proportion of cells 
in the S- and G2/M-phases while increasing cells in G1/G0 
phase [38, 39], an effect also observed by us in Glu-dCCs. 
However, in this work, melatonin-induced cell cycle 
arrests seem to be incomplete in several cases, probably 
as a consequence of the observed heterogeneity within 
cell populations. On the other hand, high concentrations 
of melatonin increased the number of hepatoma cells in 
S-phase, showing an antiproliferative effect [40] which 
was also observed by us in P19 cells cultured in galactose 
(glucose-free), glutamine/pyruvate- containing medium. 
Therefore, although melatonin induced alterations in cell 
cycle progression, those effects depend on the overall 
metabolic and differentiation state of the cancer cells. 
Even so, in the more resistant P19 Glu-CSCs, melatonin 
was able to induce an arrest at G2/M albeit without 
exerting significant cytostatic effects. Thus, in the P19 
CSCs model, melatonin was only able to reduce cell 
proliferation when the cells lost pluripotency and cell 
cycle was modified to the canonical structure.
Spontaneous Ca2+ oscillations are restricted to the 
G1/S phase transition in P19 CSCs, suggesting a role 
for Ca2+ in stem cell cycle progression [41]. In fact, we 
have recently reported that P19 stem cells present low 
cytosolic calcium levels, which are increased during cell 
differentiation [23]. The higher concentrations of free 
calcium found in P19 cells grown in galactose medium 
are correlated with the changes found on cell cycle 
progression. Accordingly, the effect of melatonin on free 
Ca2+ was also dissimilar. Glu-CSCs showed increased Ca2+ 
levels upon melatonin treatment while having no effect 
on cell viability. Conversely, melatonin-treated cells 
grown in galactose (glucose-free), glutamine/pyruvate- 
containing medium showed cell cycle arrest at S-phase, 
decreased cell viability and low intracellular free Ca2+ 
concentrations which, according with our previous results 
[23], seem to be required at high levels during the process 
of cell differentiation and mitochondrial maturation. These 
different results, which depend on the cellular metabolic 
state, are probably influenced by the lower calcium 
retention ability of mitochondria from differentiated 
cells than those from Glu-CSCs [23]. Thus, the effects of 
melatonin on calcium signaling [25, 42] may play a role 
in mediating its growth-inhibitory action in cells with an 
active mitochondrial metabolism.
Melatonin mitigates mitochondrial dysfunction 
in healthy cells, maintaining membrane potential and 
optimizing electron transport within the respiratory chain 
[8, 43, 44]. However, in some melatonin-sensitive cancer 
cells, mitochondrial depolarization is observed [45, 46]. 
Although this effect is not observed in other tumor 
cells [39], it suggests, according to our results, that the 
disruption of mitochondrial membrane potential is not 
essential for melatonin-induced antiproliferative actions. 
Despite this, P19 cells relying on oxidative metabolism 
showed a decrease in cell respiration after treatment with 
melatonin, an effect also identified in Glu-CSCs when 
maximal respiration is induced with FCCP. Although Glu-
CSCs present depolarized mitochondria and decreased 
oxygen consumption, mitochondrial respiration is not 
completely impaired as cells possess functional OXPHOS 
machinery but probably decouple respiration from ATP 
production [23]. Then, when cells undergo differentiation, 
mitochondria became polarized suggesting a different 
modulation of mitochondrial potential between stem 
and differentiated cells. While mitochondrial membrane 
potential in differentiated cells is maintained by the electron 
transport chain, in undifferentiated cells this process 
depends mostly on glycolysis and on ATP hydrolase activity 
of the F1Fo-ATPase [23]. Our results suggest a direct effect 
of melatonin in the electron transport chain, although the 
observed increase of mitochondrial membrane potential 
may not result from an inhibition of the respiratory chain 
alone but instead from effects on ATP synthase.
Previous works showed an effect of melatonin 
in inhibiting the increased respiration resulting from 
stimulation of Krebs’ cycle, protecting mitochondria from 
oxidative damage [47]. In another study, it was reported 
that melatonin decreased OXPHOS through complex IV 
inhibition while increasing the glycolytic efficiency [48], 
an effect that might explain the resistance of Glu-CSCs to 
melatonin, as well as the observed decrease in respiration 
and increased ATP levels. In our previous report, we 
demonstrated, by blocking OXPHOS with oligomycin, 
that glycolysis is the primary pathway for ATP production 
in P19 cells [23]. Although we have found here that 1mM 
melatonin also produced an increase in the ATP content in 
Gal-CSCs and Gal-dCCs, we have not found differences 
regarding the percentage of ATP on the total adenine 
nucleotide pool between controls and melatonin-treated 
cells. Thus, the energetic balance was not affected by the 
treatment with melatonin. It was described that melatonin 
maintains mitochondrial homeostasis in normal cells since 
it is able to reduce oxygen consumption while maintaining 
OXPHOS activity and ATP synthesis [49]. Despite this, 
the higher amount of adenine nucleotides observed after 
the treatment with melatonin could also be related with 
an action of melatonin in triggering and/or directing cell 
differentiation as previously described [50, 51]. This action 
would be mediated by its interaction with the retinoic-
related orphan receptor alpha (RORA) whose expression 
is temporally regulated during differentiation of P19 cells 
into neural lineages [52, 53], as probably occurs in P19 
cells grown in galactose that express higher amounts of 
the neuron-specific marker betaIII-tubulin [23]. In general, 
our data indicate that the predictable outcome of melatonin 
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treatment depends on the involvement of mitochondrial 
bioenergetics to cell metabolism.
It is known that melatonin-induced apoptosis in cancer 
cells is associated with ROS production [45, 54, 55], and 
that oxidative stress determines cancer cells fate in response 
to melatonin [11]. Here, we found a link between impaired 
oxygen consumption, mitochondrial hyperpolarization and 
oxidative stress generation in cells grown in the modified 
galactose media and treated with melatonin. Although the 
precise mechanism by which melatonin induces ROS in 
cancer cells remains unknown, our results together with 
data from other authors suggest that ROS produced by the 
mitochondrial electron transport chain constitutes a key 
factor in melatonin-induced cell death [39, 55–57] and 
differentiation [50].
Excessive ROS contributes to mitochondrial outer 
membrane permeabilization (MOMP), which is mainly 
controlled by proteins from the BCL-2 family and is 
an important factor in mediating the intrinsic apoptosis 
[56]. Previous studies have noted that melatonin alters 
the balance between BAX and BCL-2 in some cancer 
cells by up-regulating BAX expression, resulting in 
MOMP and cytochrome c release [39, 58, 59]. However, 
in other cancer cells, melatonin induces a decrease in 
BCL-2 [45, 46, 60]. Here, BAX remained unaltered 
whereas BCL-2 was down-regulated in the cells grown in 
galactose media and treated with melatonin, altering the 
BAX/BCL-2 balance but without causing cytochrome 
c release (data not shown), probably due to increased 
mitochondrial membrane potential. Accordingly, we 
have not detected an increase in caspase-3-like activity. 
Nonetheless, the Live/Dead assay suggests that the 
observed decrease in cell proliferation is due to a 
cytotoxic rather than a cytostatic action of melatonin.
Melatonin increased cytosolic AIF levels in Gal-
CSCs and Gal-dCCs, as well as in Glu-CSCs. However, 
the observed band corresponds to a 67-kDa form of AIF, 
which is the precursor form containing a mitochondrial-
localizing sequence, and which is unable to cause cell death 
[61]. On the contrary, melatonin seems to exert another 
undescribed mitochondrial effect by inducing de novo 
synthesis of the AIF precursor protein. After being imported 
into mitochondria, the mitochondrial localizing sequence 
contained in 67-kDa AIF is cleaved, resulting in the 
accumulation of the mature 57-kDa form of the AIF protein. 
This is described to translocate to the nucleus where it 
triggers a caspase-3-independent type of cell death [27]. We 
found a higher cytosolic localization of this ~57 kDa form 
of AIF in cells cultured in galactose media and treated with 
melatonin, alone or in combination with dichloroacetate, and 
in Glu-dCCs treated with melatonin and dichloroacetate.
Nonetheless, the increased percentage of dead 
cells (calcein -/ PI +) after 72 hours of treatment with 
melatonin, although moderated, was statistically significant 
(p < 0.001) in cells with a more oxidative metabolism. In 
these cells, cultured in the galactose medium, more than 50% 
of the cellular mass was lost after 72 hours of treatment with 
melatonin. Due to this, the measurement of the percentage 
of live/dead cells in the remaining population probably 
represents early (or other) events of cell death as well as 
processes of selection of the more resistant subpopulations. 
In fact, we cannot exclude divergent effects of melatonin 
in the different cell subpopulations. In accordance to 
this hypothesis, we observed a different pattern of AIF 
expression in some cells which may indicate the presence of 
different cell subpopulations with dissimilar susceptibility to 
activate this pathway (Supplementary Figure S2).
Taking all our results into account, we can infer 
that melatonin induces a toxic effect in P19 embryonal 
carcinoma cells via the inhibition of mitochondrial 
metabolism as described in other types of tumor cells 
[62]. Thus, P19 Glu-CSCs present a strong resistant 
phenotype, which seems to be linked to their glycolytic 
metabolism. In fact, we previously observed that only 
the P19 cells with an active mitochondrial metabolism 
are susceptible to the anticancer agent dichloroacetate 
[23]. Surprisingly, when we combined 1 mM melatonin 
and 10 mM dichloroacetate, cytotoxicity in the highly 
resistant Glu-CSCs was observed. These results are of 
great importance considering that to our knowledge, 
this is the only treatment showing an efficient and 
viable effect against P19 Glu-CSCs. Furthermore, the 
synergistic capability of this treatment combination was 
observed in P19 cells with the most active mitochondrial 
metabolism. The mechanism of action of dichloroacetate 
ultimately concerns the activity of PDH that, according 
to our previous results, seems to be deregulated and 
overexpressed in P19 CSCs [23]. However, upon 
melatonin treatment, no significant changes in the content 
of PDH on its active (dephosphorylated) form were 
found, which would allow us to explain its synergistic 
effect with dichloroacetate. The absence of correlation 
between the phosphorylation status of PDH and the 
observed synergistic effect reinforce the hypothesis about 
a deregulation in the PDK-PDH axis, at least in the more 
undifferentiated P19 cells. Thus, this deregulation might 
be related with the preference of primitive cells for a 
more glycolytic metabolism. In agreement, the group 
composed of more differentiated and oxidative cells (Gal-
dCCs) showed significant changes in phospho(Ser293)-
PDH when treated with melatonin and dichloroacetate. 
Since other mechanisms of PDH regulation may involve 
other phosphorylation sites [63], our results suggest the 
contribution of alternative mechanisms which might 
also be independent of the phosphorylation status of 
PDH, thus explaining part of the synergistic effect of 
the combination. For example, it was recently described 
that dichloroacetate is able to suppress mTOR activity 
specifically through pyruvate dehydrogenase kinase 4 
(PDK4) and independently of PDH [64]. Curiously, it was 
also described that Pdk4 gene expression can be increased 
by melatonin in mice [65].
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Nonetheless, the decrease of phospho(Ser293)-PDH 
observed in Gal-dCCs after treatment with melatonin, 
reinforces the idea that the anti-tumor actions of melatonin 
occur at a mitochondrial level. Accordingly, our results 
suggest that melatonin exerts its anticancer effects in P19 
cells with an active oxidative metabolism, triggering a type 
of mitochondrial cell death which is caspase-3-independent 
and is probably AIF-mediated (Figure 6). These results are 
in accordance with previous works developed in other types 
of cancer cells such as MCF-7 [66].
Mitochondrial activity, function and differentiation 
strongly impact the antitumoral ability of melatonin 
which involves, among others, the activation of intrinsic 
apoptotic pathways, in P19 embryonal carcinoma 
cells as well as in other types of cancer cells [24]. It is 
known that AIF controls programmed cells death during 
early morphogenesis and that its genetic inactivation 
renders embryonic stem cells resistant to cell death [67]. 
Consequently, the mechanism of caspase-3-independent 
cell death, stimulation of mitochondrial differentiation and 
metabolism, with consequent disruption of the Warburg 
effect constitute promissory strategies when targeting 
resistant cancer cells with an embryonic signature.
MATERIALS AND METHODS
Cell culture, differentiation and treatment
P19 embryonal carcinoma cells (CRL-1825, ATCC; 
Manassas, VA, USA) were obtained and cultured in 
glucose- or galactose (glucose-free)-containing media at 
37ºC in a 5% CO2 atmosphere. High glucose Dulbecco’s 
modified Eagle’s medium (DMEM, D5648; Sigma, St. 
Quentin Fallavier, France) was supplemented with 10% 
FBS (10270–106, Gibco; Paisley, UK), 1.8 g/l sodium 
bicarbonate (S5761, Sigma), 110 mg/l sodium pyruvate 
(P5280, Sigma) and antibiotic/antimycotic solution (A5955, 
Sigma). Galactose (glucose-free)-containing medium was 
prepared using DMEM without glucose (D5030, Sigma) 
supplemented with 10% FBS, 1.8 g/l sodium bicarbonate, 
110 mg/l sodium pyruvate, 1.8 g/l galactose (G5388, 
Sigma), 0.584 g/l L-glutamine (G3126, Sigma) and 
antibiotic/antimycotic solution. P19 cancer cells, growing 
in high glucose DMEM or in galactose (glucose free)-
containing DMEM, were maintained in monolayer and 
passaged every 2–3 days at a 1:20 to 1:30 dilution.
In order to induce cell differentiation, P19 CSCs 
were seeded at a density of 5.2 × 103 cells/cm2 and 1 μM 
of retinoic acid (R2625, Sigma) was added for 96 hours.
Melatonin (M5250, Sigma) was always freshly 
dissolved in ethanol and dichloroacetate (347795, Sigma) 
in water. If not indicated otherwise, twenty-four hours 
after seeding, P19 CSCs and dCCs grown in both culture 
media were exposed to 0.1 mM and 1 mM melatonin alone 
or in combination with 10 mM dichloroacetate (347795, 
Sigma) during 72 hours. Controls were always treated 
with an equal amount of vehicle (less than 0.95% ethanol).
Cell viability/mass
Cell mass was measured by the Sulforhodamine 
B (SRB) assay as described previously [68]. P19 cells 
Figure 6: Schematic representation summarizing the proposed role of melatonin in cancer stem cells. Our hypothesis 
ascribes an anti-tumor effect for melatonin only in differentiated cancer cells with an active oxidative metabolism, triggering a type of 
mitochondrial-mediated cell death which is likely to be characterized by an arrest at S-phase, reduction of the mitochondrial electron 
transport chain (ETC), generation of reactive oxygen species, BCL-2 down-regulation and AIF release. Thus, the treatment with melatonin 
and the stimulation of mitochondrial metabolism constitute promising strategies against resistant cancer stem cells.
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were seeded in in 48-well plates at a concentration of 
0.5 × 104 cells/ml for P19 CSCs and 2 × 104 cells/ml for 
P19 dCCs. Twenty-four hours after seeding, cells were 
treated with different melatonin concentrations (1 μM, 
10 μM, 0.1 mM and 1 mM) alone, or in combination with 
10 mM dichloroacetate. Treatments were performed from 
24 to 96 hours and samples were collected every 24 hours. 
After each period of treatment (24, 48, 72 and 96 hours), the 
medium was removed and wells rinsed with 1% PBS. Cells 
were then fixed by adding 1% acetic acid in 100% methanol 
for at least 2 hours at –20ºC. Later, the fixation solution 
was discarded and the plates dried in an oven at 37ºC. 
Next, 250 μl of 0.5% SRB in 1% acetic acid solution were 
added and incubated at 37°C for 1 hours. The wells were 
then washed with 1% acetic acid in water and dried. Then, 
500 μl of 10 mM Tris, pH 10 were added and the plates 
shaken for 30 minutes. Finally, 200 μl of each supernatant 
were transferred in 96-well plates and optical density was 
measured at 540 nm. The dose-response values IC50 (dose 
required for median effect) and the combination index were 
calculated using Compusyn software [69, 70].
After selecting the optimal time and concentration 
of melatonin treatments (0.1 mM, 1 mM melatonin for 
72 hours), we performed the trypan blue dye exclusion 
assay to measure cell viability. Treated and control P19 
cells were trypsinized and washed with PBS. 100 μl of cell 
suspension was aseptically transferred to a 1.5 ml tube and 
an equal volume of trypan blue (T8154, Sigma) was added 
for 3 minutes at room temperature. The resuspension 
was then placed in a dual-use counting slide (145–0011, 
Bio-Rad; Hercules, CA, USA) and read in a TC20 
automated cell counter (145–0102SP, Bio-Rad). Results 
are shown as percentage of live cells.
Cell cycle analysis
One million P19 cells were harvested, washed 
with PBS and fixed by adding 70% cold (–20ºC) ethanol. 
Subsequently, cells were centrifuged at 850 g to remove the 
ethanol, washed twice with PBS and finally resuspended 
in 400 μl PBS. 10 μg/ml RNAse (R5000, Sigma) and 
20 μg/ml propidium iodide (P4864, Sigma) were added 
for 30 minutes at 37ºC. 20 × 103 events per sample were 
analyzed by using a FACScalibur flow cytometer (Becton 
Dickenson, San Jose, CA, USA) with 488 nm excitation 
and 605 nm emission wavelengths. The percentage of cells 
in G1/G0, S and G2/M was determined using Modfit LT 
software (Verity Software House, Topsham, ME, USA).
Intracellular calcium measurement
Intracellular calcium levels were measured as described 
in the Fluo-4 Direct Calcium Assay kit (F10472, Invitrogen; 
Paisley, UK). After seeding 5 × 105 P19 cells in 96 well 
plates, the medium was removed and 50 μl of pre-warmed 
HBSS were added. The Fluo-4 Direct calcium reagent was 
prepared as suggested by the manufacturer and added in a 
final concentration of 2.5 mM to the plate wells containing 
HBSS. The plates were incubated for 30 minutes at 37ºC 
and fluorescence (excitation at 494 nm and emission at 516 
nm) was measured in a Gemini EM fluorescence multi-plate 
reader (Molecular Devices, Sunnyvale, CA, USA).
Mitochondrial transmembrane electric potential
The mitochondrial membrane potential in P19 cells 
was investigated by measuring tetramethylrodamine 
methyl ester (TMRM; T668, Invitrogen) fluorescence 
by flow cytometry (FACScalibur, Becton Dickinson). 
P19 cells were seeded, differentiated and treated with 
melatonin at the concentrations described above. After, 
cells were trypsinized and loaded with 150 nM TMRM for 
30 minutes and then evaluated for mean cell fluorescence 
by flow cytometry. The uncoupler carbonyl cyanide 
4-(trifluoromethoxy)phenylhydrazone (FCCP; 2 μM) was 
used as a control and was added 15 minutes after TMRM 
loading to cause mitochondrial depolarization.
Oxygen consumption
Oxygen consumption was measured polarographically 
with a Clark-type Oxygen electrode (YSI 5331, Yellow 
Springs Instruments; Yellow Springs, OH, USA) connected 
to a recorder (BD 121, Kipp&Zonen; Delft, The Netherlands) 
in a thermostated water-jacketed closed chamber with 
magnetic stirring. The reactions were performed at 37°C in 
1 ml of glucose- or galacose-containing DMEM with 5 × 106 
cells. Respiration was sustained with endogenous substrates 
followed by uncoupling by FCCP (10 μM). Respiration 
rates were obtained assuming an oxygen concentration of 
237 nmol O
2
/ml in the experimental medium at 37°C [71]. 
In order to confirm the measurement of mitochondrial basal 
respiration, 1.5 μM rotenone was added to completely inhibit 
oxygen consumption by inhibiting mitochondrial complex I 
(NADH ubiquinone oxidoreductase).
Adenine nucleotide measurement (ATP/ADP/AMP)
ATP, ADP and AMP levels were measured by 
HPLC. For adenine nucleotide extraction, after one rinse 
in cold PBS, 0.5 ml PBS and 0.5 ml perchloric acid/
EDTA were added to each dish. Cells were scraped from 
the dishes, placed in 1 ml micro-centrifuge tubes and 
centrifuged for 2 minutes at 14,000 × g. Pellets were then 
re-suspended in 50 μl of 1 M NaOH and later used for 
protein quantification by the BCA protein assay (23227, 
Thermo Scientific; Rockford, IL, USA). The supernatant 
was neutralized with 3 M KOH in 1.5 M Tris and 
centrifuged again. The supernatant was again collected 
and stored at –80°C until analyzed by reverse-phase high 
performance liquid chromatography. The chromatographic 
apparatus was a Beckman-System Gold, consisting of a 
126 Binary Pump Model and a 166 Variable UV detector, 
controlled by computer. The detection wavelength was 
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254 nm, and the column was a Lichrospher 100RP-18 
from Merck (Darmstadt, Germany). An isocratic elution 
with 100 mM phosphate buffer (KH
2
PO4), pH 6.5 and 1% 
methanol was performed with a flow rate of 1 ml/min. The 
time required for each analysis was 5 minutes.
Lipid peroxidation
The content in malondialdehyde (MDA) was 
measured by high performance liquid chromatography 
(HPLC) separation. P19 cells were harvested, washed 
and resuspended in 50 mM phosphate buffer (pH 7.4) 
and stored at –80ºC until used. Lipid peroxidation was 
assessed by the fluorimetric determination (excitation at 
515 nm and emission at 553 nm; FP-2020/2025, Jasco, 
Tokyo, Japan) of MDA adducts separated by HPLC 
(Gilson; Middleton, WI, USA) using the ClinRep complete 
kit (RECIPE; Munich, Germany).
Western blot analysis
In order to obtain total cellular extracts, P19 
cells were harvested by trypsinization, washed with 
PBS and centrifuged for 5 minutes at 1,000 g. The 
cellular pellet was resuspended in RIPA buffer (R0278; 
Sigma) supplemented with 2 mM ditiothreitol (DTT), 
100 μM phenylmethylsulfonyl fluoride (PMSF), and 
a protease inhibitor cocktail (containing 1 μg/ml of 
leupeptin, antipain, chymostatin, and pepstatin A), 
physically ruptured by sonication and kept at –80ºC 
until used. Protein contents were determined by using 
the BCA protein assay (23227; Thermo Scientific). 
After denaturation at 95ºC for 5 minutes in a Laemmli 
buffer (161–0737; BioRad, Hercules, CA, USA), 
equivalent amounts of protein (30 μg) were separated 
by electrophoresis in 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and 
electrophoretically transferred to a polyvinylidene 
difluoride (PVDF) membrane. Ponceau S staining 
was used to ensure equal loading [23]. After blocking 
membranes with 5% skim milk in TBS-T (50 mM Tris-
HCl, pH 8; 154 mM NaCl and 0.1% Tween-20) for 
1 hour at room temperature, membranes were incubated 
overnight at 4ºC with the antibodies directed against 
B-cell lymphoma 2 (BCL-2; 2870), BCL-2-associated X 
protein (BAX, 2772) and pyruvate dehydrogenase (PDH; 
3205) from Cell Signaling (Danvers, MA, USA); and 
pSer293-PDH-E1α (ab92696) from Abcam (Cambridge, 
UK), each previously diluted 1:1,000 in blocking buffer 
(1% skim milk in TBS-T). After three 5 minutes-washes 
in PBS-T, the membranes were incubated with a dilution 
(1:10, 000 in blocking buffer) of a corresponding alkaline 
phosphatase-conjugated secondary antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) for 2 hours at room 
temperature. After three washes in PBS-T for 15 minutes 
each, membranes were developed with the ECF detection 
system (RPN5785; GE Healthcare, Piscataway, NJ) 
and imaged with Versa Doc imaging system (Bio-Rad) 
according to the manufacturers’ protocols. Densities of 
each band were calculated with Quantity One Software 
(Bio-Rad) or ImageJ software. All data presented are 
representative from at least three separate experiments.
Isolation of mitochondrial and cytosolic extracts
Mitochondrial extracts were isolated harvesting 
P19 cells by trypsinization and by spinning them down 
at 1,000 g. Pellets were washed once in cold PBS and 
centrifuged again (1,000 g) at 4ºC. The cell suspension 
was then resuspended in 0.5 ml of ice cold sucrose buffer 
(250 mM sucrose, 20 mM K+ Hepes pH 7.5, 10 mM 
KCl, 1.5 mM MgCl
2
, 0.1 mM EDTA, 1 mM EGTA) 
supplemented right before use with 1 mM DTT, 0.1 mM 
PMSF and protease inhibitor cocktail containing 1 μg/
ml of leupeptin, antipain, chymostatin and pepstatin. 
The cell suspension was then incubated on ice for 20 to 
30 minutes. After incubation, cells were transferred to a 
pre-cooled tissue homogenizer and homogenized 30 times 
using a tight pestle, while keeping the homogenizer on 
ice. Progress was monitored every 20 to 30 strokes under 
a phase contrast microscope and was stopped when more 
than 90% of cells were burst.
Homogenized cells were centrifuged at 3,500 g 
for 5 minutes at 4ºC. The supernatant, containing the 
mitochondrial and cytosolic fractions was collected. Then, 
the collected supernatant was centrifuged again at 10,000 
g during 15 minutes at 4ºC. The pellet, corresponding to 
the mitochondrial fraction was resuspended in 50 μl of 
sucrose buffer cited above. The supernatant was again 
centrifuged at 100,000 g during 30 minutes at 4ºC. The 
resulting supernatant contained the cytosolic fraction and 
was lyophilized in order to concentrate the protein and 
resuspended in 50 μl of the same sucrose buffer.
Specific proteins in both fractions were semi-
quantified by western blotting as described above using 
antibodies against AIF (sc-13116) from Santa Cruz 
Biotechnology and cytochrome c (556433) from Becton 
Dickenson. Densitometry values were normalized to the 
levels of Ponceau S for cytosolic extracts, and to the 
content in translocase of the outer membrane 20 (TOM20) 
(sc-11415; Santa Cruz Biotechnology) for mitochondrial 
extracts.
Caspase 3-like activity
P19 cells were trypsinized and washed in PBS. 
After washing, cells were concentrated by centrifuging at 
300 g for 3 minutes and the supernatant was discarded. 
The pellets were resuspended in a lysis buffer containing 
100 mM NaCl, 0.1% CHAPS, 1 mM DTT, 0.1 mM EDTA, 
50 mM HEPES pH 7.4. The samples were kept on ice for 
20 minutes following by protein quantification through the 
BCA kit assay (23227; Thermo Scientific). Then, 25 μg of 
Oncotarget17094www.impactjournals.com/oncotarget
cell protein extracts were aliquoted in an assay buffer (100 
mM NaCl, 0.1% CHAPS, 1 mM DTT, 0.1 mM EDTA, 
10% glycerol, 50 mM HEPES pH 7.4) supplemented with 
100 μM caspase-3 substrate Ac-DEVD-pNA (235400; 
Merck Millipore, Darmstadt, Germany) and incubated 
for 2 hours at 37ºC. Caspase 3-like activity was accessed 
following the detection of the chromophore p-nitroaniline 
(pNA) after cleavage from the labeled substrate 
Ac-DEVD-pNA. Method calibration was achieved using 
known concentrations of p-NA.
Live/dead assay
Calcein-AM (C1430; Invitrogen) and propidium 
iodide (P4864; Sigma Aldrich) were used to determine the 
percentages of viable and dead cells. After the treatments 
with melatonin, 106 P19 cells were harvested, washed, 
resuspended in HBSS/Ca and loaded with 0.1 μM calcein-
AM and 8 μM propidium iodide for 20 minutes at room 
temperature. Fluorescence was measured by FACS 
(Becton Dickinson FACScalibur) with 488 nm excitation 
wavelength. The simultaneous measurement of Calcein/
propidium iodide fluorescence was performed using 
530/30 nm bandpass filter for Calcein and a 610/20 nm 
bandpass filter for propidium iodide red fluorescence.
Statistical analyses
Data are mean values ± SEM and multiple comparisons 
were carried out using ANOVA followed by the Bonferroni 
post hoc test. Significance was accepted with p < 0.05.
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